Ізраїль - англійська - Ministry of Health

ferring pharmaceuticals ltd - mesalazine - enema - mesalazine 1 g / 100 ml - aminosalicylic acid and similar agents - ulcerative colitis - chron's disease

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - granisetron hydrochloride - concentrate for solution for injection - 3mg/3ml - serotonin (5ht3) antagonists; granisetron

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - granisetron hydrochloride - concentrate for solution for injection - 1 milligram(s)/millilitre - serotonin (5ht3) antagonists

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - hyoscine hydrobromide - solution for injection - 600 microgram(s)/millilitre - other antiemetics

Велика Британія - англійська - myHealthbox

rosemont pharmaceuticals ltd - rivastigmine hydrogen tartrate - oral solution - 2mg for ml - psychoanaleptics, anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia; symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Велика Британія - англійська - myHealthbox

rosemont pharmaceuticals ltd - amlodipine - oral solution - 2 mg/ml - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension; chronic stable angina pectoris; vasospastic (prinzmetal's) angina

Велика Британія - англійська - myHealthbox

rosemont pharmaceuticals ltd - amlodipine - oral solution - 1mg/ml - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension; chronic stable angina pectoris; vasospastic (prinzmetal's) angina

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - clobazam - oral suspension - 1 milligram(s)/millilitre - benzodiazepine derivatives; clobazam - anxiolytics - it is indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, perizam must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. perizam may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.

Велика Британія - англійська - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 10mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy

Велика Британія - англійська - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 20mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy